The NOVOS Core clinical trial, peer-reviewed and published in European Heart Journal Open in November 2026, asked whether a daily supplement formulated using research on the biology of aging would change how blood vessels work. This article covers why the researchers measured artery function, how they set up the trial, what participants did each day, and how to take NOVOS Core the same way participants did.
Quick Overview
- The trial measured blood vessels because they show signs of aging years before symptoms appear, and they supply every organ in the body.
- University of Surrey researchers ran the trial with colleagues from Royal Surrey NHS Foundation Trust. It was randomized, double-blind, and placebo-controlled.
- Sixty-one generally healthy, non-smoking adults aged 40 and over took one 15-gram serving of NOVOS Core or a matching placebo every day for six months. Just over half were women.
- The main outcome, flow-mediated dilation, was set before the trial began. The six-month readings were taken fasted, about 24 hours after each participant’s last serving.
- To follow the trial at home, take one sachet a day mixed into water for six months.
Why Blood Vessels?
To test whether a supplement supports healthy aging, researchers need something they can measure that changes early, before any symptoms appear. Blood vessels meet that need. They start to show signs of aging years before a person notices anything. Because they carry blood to every organ, they are a common focus of research on healthy aging.
NOVOS Core’s ingredients were selected using research on the biological hallmarks of aging. Each of its 12 ingredients was selected for evidence that it acts on several hallmarks, for links to longevity in scientific studies, and for decades of safe human use. Blood vessel function was a logical first place to test a formula.
Who Ran the Trial
The trial was investigator-initiated, meaning university researchers led it. Christian Heiss, Professor of Cardiovascular Medicine at the University of Surrey and an internationally recognized expert in measuring endothelial function, ran it with colleagues at Royal Surrey NHS Foundation Trust. It is registered on ClinicalTrials.gov (NCT06145087).
NOVOS supplied the product, the matching placebo, and an unrestricted contribution toward research costs. NOVOS had no role in study design, data collection, primary interpretation of the data, or the decision to publish. The University of Surrey researchers kept control of the study data. One of the seven authors, Diogo Barardo, PhD, is a NOVOS employee; he independently reproduced the statistical analyses.
See also: What Peer Review Means for the NOVOS Core Clinical Trial
How the Trial Was Set Up
Four features of the trial’s design make its results more reliable: blinding, healthy volunteers, a main outcome chosen in advance, and fasted measurements.
Randomized and Double-Blind
Participants were randomly assigned to NOVOS Core or a placebo matched for look and taste. Neither the participants nor the researchers knew who was taking which, so expectations were unlikely to sway the results.
Healthy Volunteers
The trial enrolled 61 generally healthy, non-smoking adults aged 40 and over. Of those, 33 took NOVOS Core, and 28 took the placebo. People with unstable cardiovascular disease, heart rhythm disorders, or active cancer were excluded. Healthy volunteers’ measures were already in normal ranges, which leaves little room to improve and makes a measurable change harder to achieve.
Thirty-one of the 61 participants were women. Across 1,079 cardiovascular trials registered from 2017 to 2023, women made up 41% of participants.
A Main Outcome Set in Advance
The researchers chose flow-mediated dilation (FMD) as the primary outcome before the trial began. It is the main outcome listed on the trial’s registry record. FMD uses ultrasound to measure how well the main artery in the upper arm widens when blood flow increases. Pulse wave velocity, a measure of arterial flexibility, and systolic blood pressure were secondary outcomes.
Measured on an Empty Stomach
Blood vessel readings can shift after a meal, so measurements were taken in a fasted state. The six-month readings came about 24 hours after each participant’s last serving, so they captured the effect of six months of daily use. Researchers also measured FMD one hour after the first serving.
See also: What the NOVOS Core Clinical Trial Found, in Plain English
What Participants Did Each Day
According to the trial protocol, participants mixed one serving of NOVOS Core into a glass of water (240 ml) and drank it in the morning with breakfast. They did this every day for six months, with two phone check-ins along the way to help them stay on track.
The trial tested NOVOS Core on its own. Participants stopped fish oil and NAD+ boosters, such as NMN, 21 days before the trial and for its full length. People already taking supplements with the same ingredients as the formula weren’t eligible.
NOVOS Boost provides NMN, so the combination wasn’t part of the trial. You can take Boost and Core together for a more comprehensive longevity routine, but that’s a different routine from the one the trial tested.
How To Follow the Trial at Home
Here is how to take NOVOS Core the way participants did:
- Take one sachet mixed into water each day. NOVOS says most customers take it in the morning and that consistent daily use matters more than the time of day. Taking it with breakfast, as participants did, ties it to a habit you already have.
- Plan on at least six months, the length of the trial.
- If you take prescription medications or have a medical condition, share the ingredient list with your healthcare provider before you start.
Start Your Protocol
The trial’s results came from six months of daily use of NOVOS Core on its own. Start your protocol with NOVOS Core, or choose the Longevity Kit, which pairs a year of Core with Boost and a NOVOS Age test.
FAQ About How the NOVOS Core Trial Was Run
What is the STAMINA trial?
STAMINA is the name of the NOVOS Core clinical trial. The name comes from its registered title, “Effects of a Supplement to Target Aging Mechanisms on Vascular Function.”
Is the NOVOS Core sold today the same formula used in the trial?
Yes. NOVOS says the finished NOVOS Core formula was studied in the randomized, double-blind, placebo-controlled trial in healthy adults aged 40 and over.
Can I take NOVOS Core with fish oil?
The trial asked participants to stop fish oil 21 days before and during the study, so it didn’t test the two together. Ask your healthcare provider whether the combination suits you.
What will NOVOS study next?
NOVOS is evaluating follow-up studies of NOVOS Core in muscle function, brain and cognition, and skin, along with further analysis of its effects on the biological aging process.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Journal names are given for reference only and do not imply endorsement by the journals, their publishers, or the European Society of Cardiology.
